CLOVIS ONCOLOGY INC's ticker is and the CUSIP is 189464AB6. A total of 12 filers reported holding CLOVIS ONCOLOGY INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $110,000 | +5.8% | 110,000 | 0.0% | 0.00% | 0.0% |
Q1 2021 | $104,000 | +1.0% | 110,000 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $103,000 | 0.0% | 110,000 | 0.0% | 0.00% | 0.0% |
Q3 2020 | $103,000 | +2.0% | 110,000 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $101,000 | +3.1% | 110,000 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $98,000 | +2.1% | 110,000 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $96,000 | -82.5% | 110,000 | -82.5% | 0.00% | -66.7% |
Q3 2019 | $550,000 | -2.1% | 630,000 | 0.0% | 0.00% | -25.0% |
Q2 2019 | $562,000 | +15.6% | 630,000 | +21.2% | 0.00% | 0.0% |
Q1 2019 | $486,000 | -29.9% | 520,000 | -37.0% | 0.00% | -33.3% |
Q4 2018 | $693,000 | -10.5% | 825,000 | 0.0% | 0.01% | 0.0% |
Q3 2018 | $774,000 | -13.1% | 825,000 | 0.0% | 0.01% | 0.0% |
Q2 2018 | $891,000 | +16.0% | 825,000 | +25.0% | 0.01% | +20.0% |
Q1 2018 | $768,000 | -13.8% | 660,000 | 0.0% | 0.01% | -84.8% |
Q4 2017 | $891,000 | +60.0% | 660,000 | +83.3% | 0.03% | +57.1% |
Q3 2017 | $557,000 | – | 360,000 | – | 0.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
LINDEN ADVISORS LP | 69,346,000 | $107,321,000 | 3.81% |
PFM Health Sciences, LP | 34,710,000 | $53,670,000 | 1.06% |
Partner Investment Management, L.P. | 556,000 | $860,000 | 0.82% |
Myriad Asset Management Ltd. | 5,000,000 | $7,731,000 | 0.75% |
SYMPHONY ASSET MANAGEMENT LLC | 4,000,000 | $6,185,000 | 0.69% |
CAPSTONE INVESTMENT ADVISORS, LLC | 9,074,000 | $14,030,000 | 0.49% |
CSS LLC/IL | 5,251,000 | $8,112,000 | 0.40% |
SSI INVESTMENT MANAGEMENT LLC | 2,813,000 | $4,333,000 | 0.37% |
ADVENT CAPITAL MANAGEMENT /DE/ | 7,131,000 | $11,056,000 | 0.21% |
D. E. Shaw & Co., Inc. | 27,750,000 | $42,835,000 | 0.07% |